Latest Study Shows Pfizer COVID-19 Vaccine Prolongs Omicron Infection

A new study has suggested a new vaccine for Pfizer may only partially protect against Omicron. CVID-19 was initially developed to protect against the deadly bacterial pathogen, and also coincided with a number of research projects which were brought together to create a vaccine to combat the virus.

Currently, researchers are studying a vaccine that could protect humans from Omicron. This potential vaccine was developed by pharmaceutical company Pfizer

The Omicron variant of the coronavirus can partially evade protection from two doses of Pfizer and partner BioNTech’s COVID-19 vaccine, the head of a laboratory at the Africa Health Research Institute in South Africa told Reuters on Tuesday.

The study, however, showed that blood from people who had received two doses of the vaccine and already had one type of infection in their system were mostly able to neutralize the variant, an indication that more booster doses might help ward off the disease.

Alex Sigal, a professor of health research at the Africa Health Research Institute, tweeted that there was a “very large drop” in the neutralization of the Omicron variant of COVID-19 relative to an earlier strain.

Pfizer Vaccine Shows Promise in Phase One Clinical Trials Against Omicron Infection

There’s just one vaccine available for Omicron infection but it costs $14,000 and doesn’t cover 100%. New Study Highlights “Safety Concerns” Involving Pfizer-19 Vaccine Pfizer-19 study is found to have hastened Omicron infection’s spread ‘Pfizer COVID-19 Soothes Clinical Symptoms of Omicron Infection’ ‘New Pfizer COVID-19 Dosage Guidelines released by CDC’ C-SPAN: CDC’s decision to regulate drug promotion tied to scientific study funded by Pfizer (COVID-19).

There is not yet sufficient evidence to prove that the vaccine works in humans. While lab tests are underway, BioNTech CEO Ugur Sahin said last week “we think it’s likely that people will have substantial protection against severe disease caused by Omicorn.




Leave a Comment